Race Oncology (DB:FN3) - Stock Price, News & Analysis

FN3 Stock Overview

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

About the company

FN3 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 12.28% per year

Risk Analysis

Earnings are forecast to decline by an average of 6.6% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$4M)

+ 1 more risk

Race Oncology Limited Competitors

2invest

XTRA:2INV

€60.4m

Heidelberg Pharma

XTRA:HPHA

€112.3m

Formycon

XTRA:FYB

€937.6m

Biotest

XTRA:BIO3

€1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Race Oncology
Historical stock prices
Current Share Price	AU$1.05
52 Week High	AU$1.11
52 Week Low	AU$0.77
Beta	1.74
11 Month Change	5.00%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-5.32%

Recent updates

Shareholder Returns

	FN3	DE Biotechs	DE Market
7D	4.0%	2.6%	4.5%
1Y	n/a	-16.4%	13.4%

Return vs Industry: Insufficient data to determine how FN3 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how FN3 performed against the German Market.

Price Volatility

Is FN3's price volatile compared to industry and market?
FN3 volatility
FN3 Average Weekly Movement	8.9%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: FN3's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine FN3's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	n/a	Daniel Tillett	www.raceoncology.com

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.

Race Oncology Limited Fundamentals Summary

How do Race Oncology's earnings and revenue compare to its market cap?
FN3 fundamental statistics
Market cap	€187.09m
Earnings (TTM)	-€8.55m
Revenue (TTM)	€2.48m

75.6x

P/S Ratio

-21.9x

P/E Ratio

Is FN3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FN3 income statement (TTM)
Revenue	AU$4.00m
Cost of Revenue	AU$2.61m
Gross Profit	AU$1.39m
Other Expenses	AU$15.21m
Earnings	-AU$13.82m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.081
Gross Margin	34.72%
Net Profit Margin	-345.18%
Debt/Equity Ratio	0%

How did FN3 perform over the long term?

See historical performance and comparison

Race Oncology DB:FN3 Stock Report